Pitolisant (Wakix) in children ages 6 years and up led to clinically meaningful improvements in narcolepsy symptoms in a phase III trial. Among 110 kids with narcolepsy with or without cataplexy, ...
On Wednesday, Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for pitolisant for excessive daytime sleepiness ...
Credit: Getty Images. Pitolisant is a selective histamine-3 receptor antagonist/inverse agonist. The Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisant for the ...
Dublin, Aug. 03, 2023 (GLOBE NEWSWIRE) -- The "Pitolisant Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering. This report offers a ...
Discover comprehensive details about Pitolisant, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...
Review the side-effects of Pitolisant as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...
PITTSBURGH, Oct. 15, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has acquired Aculys Pharma, Inc., a clinical stage biopharmaceutical company ...
Harmony Biosciences (HRMY) announced results from its bioequivalence study evaluating pitolisant gastro-resistant formulation. With findings from both the pivotal BE and dosing optimization studies, ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. At the 1-year mark of pitolisant treatment, the Epworth ...
Please provide your email address to receive an email when new articles are posted on . Treatment with pitolisant, as compared with placebo, reduced excessive daytime sleepiness and improved several ...
The appraisal committee considered evidence submitted by Bioprojet Pharma, a review of this submission by the evidence review group (ERG), NICE's technical report, and responses from stakeholders. See ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback